D
Danilo R. Casimiro
Researcher at Merck & Co.
Publications - 74
Citations - 6304
Danilo R. Casimiro is an academic researcher from Merck & Co.. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 32, co-authored 74 publications receiving 5893 citations. Previous affiliations of Danilo R. Casimiro include Scripps Research Institute & Sanofi Pasteur.
Papers
More filters
Journal ArticleDOI
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Susan Buchbinder,Devan V. Mehrotra,Ann Duerr,Daniel W. Fitzgerald,Robin Mogg,David Li,Peter B. Gilbert,Javier R. Lama,Michael Marmor,Carlos del Rio,M. Juliana McElrath,Danilo R. Casimiro,Keith Gottesdiener,Chodakewitz Jeffrey A,Lawrence Corey,Michael N. Robertson +15 more
TL;DR: This cell-mediated immunity vaccine did not prevent HIV-1 infection or reduce early viral level and Mechanisms for insufficient efficacy of the vaccine and the increased HIV- 1 infection rates in subgroups of vaccine recipients are being explored.
Patent
Pd-1 binding proteins
TL;DR: In this article, a subset of PD-1 binding proteins are employed to modulate the immune system through the manipulation of the PD1 signaling pathway, enhancing host immunity to treat infections and cancer.
Journal ArticleDOI
Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
Danilo R. Casimiro,Ling Chen,Tong-Ming Fu,Robert K. Evans,Michael J. Caulfield,Mary-Ellen Davies,Aimin Tang,Minchun Chen,Lingyi Huang,Virginia Harris,Daniel C. Freed,Keith A. Wilson,Sheri Dubey,De-Min Zhu,Denise K. Nawrocki,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,William M. Hurni,Zheng Xu,Jeffrey G. Smith,Su Wang,Xu Liu,Liming Guan,Romnie Long,Wendy L. Trigona,Gwendolyn J. Heidecker,Helen C. Perry,Natasha Persaud,Timothy J. Toner,Qin Su,Xiaoping Liang,Rima Youil,Michael Chastain,Andrew J. Bett,David B. Volkin,Emilio A. Emini,John W. Shiver +38 more
TL;DR: Results are suggestive of an immunization strategy for humans that is centered on use of the adenovirus vector and in which existing adenavirus immunity may be overcome by combined immunization with adjuvanted DNA and adenvirus vector boosting.
Journal ArticleDOI
Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag
Danilo R. Casimiro,Fubao Wang,William A. Schleif,Xiaoping Liang,Zhiqiang Zhang,Timothy W. Tobery,Mary-Ellen Davies,Adrian B. McDermott,David H. O’Connor,Arthur Fridman,Ansu Bagchi,Lynda G. Tussey,Andrew J. Bett,Adam C. Finnefrock,Tong-Ming Fu,Aimin Tang,Keith A. Wilson,Minchun Chen,Helen C. Perry,Gwendolyn J. Heidecker,Daniel C. Freed,Anthony Carella,Kara Punt,Kara J. Sykes,Lingyi Huang,Virginia I. Ausensi,Margaret Bachinsky,Usha Sadasivan-Nair,David I. Watkins,Emilio A. Emini,John W. Shiver +30 more
TL;DR: The prophylactic efficacy of DNA and replication-incompetent adenovirus serotype 5 (Ad5) vaccine vectors expressing simian immunodeficiency virus (SIV) Gag was examined in rhesus macaques using an SIVmac239 challenge, and virus control was short-lived.
Journal ArticleDOI
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Frances Priddy,Deborah D. Brown,James G. Kublin,Kathleen Monahan,David Wright,Jacob Lalezari,Steven Santiago,Michael Marmor,Michelle Lally,Richard M. Novak,Stephen J. Brown,Priya Kulkarni,Sheri Dubey,Lisa S. Kierstead,Danilo R. Casimiro,Robin Mogg,Mark J. DiNubile,John W. Shiver,Randi Y. Leavitt,Michael N. Robertson,Devan V. Mehrotra,Erin Quirk +21 more
TL;DR: The vaccine was generally well tolerated and induced cell-mediated immune responses against human immunodeficiency virus type 1 peptides in most healthy adults and vaccination in a proof-of-concept trial with use of this vaccine was discontinued because of lack of efficacy.